PMDA drug package insert
ミルタザピン錠15mg「KMP」
PMDA Prescription drug · 共創未来ファーマ株式会社 · package insert Oct 10, 2024
Key facts
| Brand names | ミルタザピン錠15mg「KMP」, ミルタザピン錠30mg「KMP」 |
|---|---|
| Nonproprietary names | ミルタザピン |
| Companies | 製造販売元／共創未来ファーマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | ノルアドレナリン・セロトニン作動性抗うつ剤 |
| Therapeutic category codes | 871179 |
| YJ codes | 1179051F1223, 1179051F2220 |
| Approval numbers | 30500AMX00147000, 30500AMX00148000 |
| Package insert edition | 第3版 |
| Package insert date | Oct 10, 2024 |
| PMDA document key | 300166_1179051F1223_1 |
| PMDA company code | 300166 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: